🥊 FROM THE PPP ARCHIVES | The Human Story
Most people know Ken Shamrock as a legend of mixed martial arts.
But there's much more to his story than what happened inside the Octagon.
In this wide-ranging conversation, we explored his journey through professional fighting, faith supporting wounded warriors, and his perspectives on longevity, recovery, and emerging approaches in sports medicine.
A fascinating look at resilience, reinvention, and finding purpose beyond professional competition.
🎙️ Rediscover BEYOND THE OCTAGON on Progress, Potential and Possibilities.
youtube.com/watch?v=xUDGN6…
#KenShamrock #MMA #Longevity #Resilience
Most people know Ken Shamrock as a legend of mixed martial arts.
But there's much more to his story than what happened inside the Octagon.
In this wide-ranging conversation, we explored his journey through professional fighting, faith supporting wounded warriors, and his perspectives on longevity, recovery, and emerging approaches in sports medicine.
A fascinating look at resilience, reinvention, and finding purpose beyond professional competition.
🎙️ Rediscover BEYOND THE OCTAGON on Progress, Potential and Possibilities.
youtube.com/watch?v=xUDGN6…
#KenShamrock #MMA #Longevity #Resilience
0
0
2
43
🧬 FROM THE PPP ARCHIVES | Ahead of the Curve
The mRNA revolution didn't end with COVID-19 vaccines. In many ways, it was just getting started.
In this conversation, I spoke with 2023 Nobel laureate Dr. Drew Weissman, whose pioneering work helped make mRNA vaccines possible.
We explore RNA science and its potential to transform how we prevent and treat disease.
From infectious diseases to cancer immunotherapy and emerging RNA-based medicines, the scientific possibilities are extraordinary—but so are the challenges of turning them into effective treatments.
🎙️ Revisit this conversation on Progress, Potential and Possibilities.
youtube.com/watch?v=CtTuXA…
#RNA #mRNA #Biotechnology #MedicalInnovation
The mRNA revolution didn't end with COVID-19 vaccines. In many ways, it was just getting started.
In this conversation, I spoke with 2023 Nobel laureate Dr. Drew Weissman, whose pioneering work helped make mRNA vaccines possible.
We explore RNA science and its potential to transform how we prevent and treat disease.
From infectious diseases to cancer immunotherapy and emerging RNA-based medicines, the scientific possibilities are extraordinary—but so are the challenges of turning them into effective treatments.
🎙️ Revisit this conversation on Progress, Potential and Possibilities.
youtube.com/watch?v=CtTuXA…
#RNA #mRNA #Biotechnology #MedicalInnovation
0
0
2
79
🔬 FROM THE PPP ARCHIVES | The Big Question
What if cells could be instructed to build, repair, and regenerate complex biological structures?
In this fascinating conversation, I sat down with Dr. Michael Levin of Tufts University to explore bioelectric signaling, morphogenesis, cells coordinate to create living anatomy.
Could understanding the body's bioelectric code fundamentally change regenerative medicine?
An extraordinary conversation at the intersection of developmental biology, bioengineering, and the future of medicine.
🎙️ Rediscover this episode of Progress, Potential and Possibilities.
youtube.com/watch?v=4d2SC3…
#RegenerativeMedicine #Bioelectricity #DevelopmentalBiology #PPP
What if cells could be instructed to build, repair, and regenerate complex biological structures?
In this fascinating conversation, I sat down with Dr. Michael Levin of Tufts University to explore bioelectric signaling, morphogenesis, cells coordinate to create living anatomy.
Could understanding the body's bioelectric code fundamentally change regenerative medicine?
An extraordinary conversation at the intersection of developmental biology, bioengineering, and the future of medicine.
🎙️ Rediscover this episode of Progress, Potential and Possibilities.
youtube.com/watch?v=4d2SC3…
#RegenerativeMedicine #Bioelectricity #DevelopmentalBiology #PPP
0
0
3
86
⚛️ Can nuclear power go small? And could that help power the AI revolution?
AI data centers, critical infrastructure and industrial facilities all need something that is becoming increasingly valuable: reliable, around-the-clock electricity.
On this @ProgressPotent1 episode, ibson_, Founder and CEO of @hadron_energy , to explore the company's Halo microreactor - a proposed 10-megawatt electric light-water reactor designed around an integrated, factory-oriented approach.
We discuss:
🔹 Why pursue a microreactor rather than a conventional nuclear plant?
🔹 How does a light-water reactor generate electricity, and what does its thermal output tell us?
🔹 What does “walk-away safe” actually mean - and what evidence is needed to demonstrate it?
🔹 Could factory manufacturing make nuclear power more affordable and easier to deploy?
🔹 How do uranium enrichment, fuel fabrication and America's domestic nuclear fuel supply chain affect the strategy?
🔹 What still stands between a promising design and a commercially operating reactor?
The opportunity is compelling. So are the challenges: licensing, capital requirements, fuel availability, first-of-a-kind costs and proving that the economics work.
Can a smaller nuclear reactor deliver a genuinely different energy business model?
Join us as we examine the technology, the strategy and the road to commercialization.
#NuclearEnergy #Microreactors #AIDataCenters #EnergyInnovation #ProgressPotentialAndPossibilities @CoreIR_
AI data centers, critical infrastructure and industrial facilities all need something that is becoming increasingly valuable: reliable, around-the-clock electricity.
On this @ProgressPotent1 episode, ibson_, Founder and CEO of @hadron_energy , to explore the company's Halo microreactor - a proposed 10-megawatt electric light-water reactor designed around an integrated, factory-oriented approach.
We discuss:
🔹 Why pursue a microreactor rather than a conventional nuclear plant?
🔹 How does a light-water reactor generate electricity, and what does its thermal output tell us?
🔹 What does “walk-away safe” actually mean - and what evidence is needed to demonstrate it?
🔹 Could factory manufacturing make nuclear power more affordable and easier to deploy?
🔹 How do uranium enrichment, fuel fabrication and America's domestic nuclear fuel supply chain affect the strategy?
🔹 What still stands between a promising design and a commercially operating reactor?
The opportunity is compelling. So are the challenges: licensing, capital requirements, fuel availability, first-of-a-kind costs and proving that the economics work.
Can a smaller nuclear reactor deliver a genuinely different energy business model?
Join us as we examine the technology, the strategy and the road to commercialization.
#NuclearEnergy #Microreactors #AIDataCenters #EnergyInnovation #ProgressPotentialAndPossibilities @CoreIR_
0
1
5
193
⚛️ Can nuclear power go small? And could that help power the AI revolution?
AI data centers, critical infrastructure and industrial facilities all need something that is becoming increasingly valuable: reliable, around-the-clock electricity.
On this @ProgressPotent1 episode, ibson_, Founder and CEO of @hadron_energy, to explore the company's Halo microreactor - a proposed 10-megawatt electric light-water reactor designed around an integrated, factory-oriented approach.
We discuss:
🔹 Why pursue a microreactor rather than a conventional nuclear plant?
🔹 How does a light-water reactor generate electricity, and what does its thermal output tell us?
🔹 What does “walk-away safe” actually mean - and what evidence is needed to demonstrate it?
🔹 Could factory manufacturing make nuclear power more affordable and easier to deploy?
🔹 How do uranium enrichment, fuel fabrication and America's domestic nuclear fuel supply chain affect the strategy?
🔹 What still stands between a promising design and a commercially operating reactor?
The opportunity is compelling. So are the challenges: licensing, capital requirements, fuel availability, first-of-a-kind costs and proving that the economics work.
Can a smaller nuclear reactor deliver a genuinely different energy business model?
Join us as we examine the technology, the strategy and the road to commercialization.
Watch now - youtube.com/watch?v=X32NEn…
#NuclearEnergy #Microreactors #AIDataCenters #EnergyInnovation #ProgressPotentialAndPossibilities @CoreIR_
AI data centers, critical infrastructure and industrial facilities all need something that is becoming increasingly valuable: reliable, around-the-clock electricity.
On this @ProgressPotent1 episode, ibson_, Founder and CEO of @hadron_energy, to explore the company's Halo microreactor - a proposed 10-megawatt electric light-water reactor designed around an integrated, factory-oriented approach.
We discuss:
🔹 Why pursue a microreactor rather than a conventional nuclear plant?
🔹 How does a light-water reactor generate electricity, and what does its thermal output tell us?
🔹 What does “walk-away safe” actually mean - and what evidence is needed to demonstrate it?
🔹 Could factory manufacturing make nuclear power more affordable and easier to deploy?
🔹 How do uranium enrichment, fuel fabrication and America's domestic nuclear fuel supply chain affect the strategy?
🔹 What still stands between a promising design and a commercially operating reactor?
The opportunity is compelling. So are the challenges: licensing, capital requirements, fuel availability, first-of-a-kind costs and proving that the economics work.
Can a smaller nuclear reactor deliver a genuinely different energy business model?
Join us as we examine the technology, the strategy and the road to commercialization.
Watch now - youtube.com/watch?v=X32NEn…
#NuclearEnergy #Microreactors #AIDataCenters #EnergyInnovation #ProgressPotentialAndPossibilities @CoreIR_
0
1
5
224
🧬 HOW DO YOU BUILD A SUCCESSFUL BIOTECH COMPANY IN A WORLD THAT NEVER STOPS CHANGING?
From rapidly evolving technologies and AI to shifting regulations, payer dynamics, and the economics of drug development, building a biotech company today requires far more than promising ressPotent1 episode, I'm joined by Dr. Stella Vnook - pharmaceutical executive, biotech entrepreneur, and founder of Oral BioLife and AVIVA Ventures.
With more than 25 years of experience spanning Merck, Catalent, and multiple biotechnology ventures, Stella brings a unique perspective on what it takes to turn scientific discoveries into real-world medical innovations.
We explore:
🦷 Regenerative dentistry: @oralbiolife and their Ambrilux Dental Gel is being developed to stimulate bone regeneration in periodontal disease. How is the technology intended to work, and what evidence will be needed to demonstrate its effectiveness in humans?
🧪 The next generation of biotech: Why do promising scientific discoveries so often struggle to become successful treatments - and how can we improve the journey from laboratory to patient?
🤖 AI and drug development: Where can AI genuinely accelerate pharmaceutical innovation, and where do the hardest scientific and clinical challenges remain?
💡 The business of healthcare innovation: How do funding, commercialization, reimbursement, and patient access determine whether a medical breakthrough ultimately makes a difference?
Dr. Vnook is also being recognized by @TempleUniv School of Pharmacy - @TU_SP - with its Pharmaceutical Innovation Award as the university celebrates its 125th anniversary.
Join us for a forward-looking, evidence-focused conversation about regenerative medicine, biotechnology, and the future of healthcare.
#Biotech #Biotechnology #AIinHealthcare #DrugDevelopment #HealthcareInnovation #ProgressPotentialAndPossibilities @KafkaMediaGroup
From rapidly evolving technologies and AI to shifting regulations, payer dynamics, and the economics of drug development, building a biotech company today requires far more than promising ressPotent1 episode, I'm joined by Dr. Stella Vnook - pharmaceutical executive, biotech entrepreneur, and founder of Oral BioLife and AVIVA Ventures.
With more than 25 years of experience spanning Merck, Catalent, and multiple biotechnology ventures, Stella brings a unique perspective on what it takes to turn scientific discoveries into real-world medical innovations.
We explore:
🦷 Regenerative dentistry: @oralbiolife and their Ambrilux Dental Gel is being developed to stimulate bone regeneration in periodontal disease. How is the technology intended to work, and what evidence will be needed to demonstrate its effectiveness in humans?
🧪 The next generation of biotech: Why do promising scientific discoveries so often struggle to become successful treatments - and how can we improve the journey from laboratory to patient?
🤖 AI and drug development: Where can AI genuinely accelerate pharmaceutical innovation, and where do the hardest scientific and clinical challenges remain?
💡 The business of healthcare innovation: How do funding, commercialization, reimbursement, and patient access determine whether a medical breakthrough ultimately makes a difference?
Dr. Vnook is also being recognized by @TempleUniv School of Pharmacy - @TU_SP - with its Pharmaceutical Innovation Award as the university celebrates its 125th anniversary.
Join us for a forward-looking, evidence-focused conversation about regenerative medicine, biotechnology, and the future of healthcare.
#Biotech #Biotechnology #AIinHealthcare #DrugDevelopment #HealthcareInnovation #ProgressPotentialAndPossibilities @KafkaMediaGroup
0
1
4
208
🧬 HOW DO YOU BUILD A SUCCESSFUL BIOTECH COMPANY IN A WORLD THAT NEVER STOPS CHANGING?
From rapidly evolving technologies and AI to shifting regulations, payer dynamics, and the economics of drug development, building a biotech company today requires far more than promising ressPotent1 episode, I'm joined by Dr. Stella Vnook - pharmaceutical executive, biotech entrepreneur, and founder of Oral BioLife and AVIVA Ventures.
With more than 25 years of experience spanning Merck, Catalent, and multiple biotechnology ventures, Stella brings a unique perspective on what it takes to turn scientific discoveries into real-world medical innovations.
We explore:
🦷 Regenerative dentistry: @oralbiolife and their Ambrilux Dental Gel is being developed to stimulate bone regeneration in periodontal disease. How is the technology intended to work, and what evidence will be needed to demonstrate its effectiveness in humans?
🧪 The next generation of biotech: Why do promising scientific discoveries so often struggle to become successful treatments - and how can we improve the journey from laboratory to patient?
🤖 AI and drug development: Where can AI genuinely accelerate pharmaceutical innovation, and where do the hardest scientific and clinical challenges remain?
💡 The business of healthcare innovation: How do funding, commercialization, reimbursement, and patient access determine whether a medical breakthrough ultimately makes a difference?
Dr. Vnook is also being recognized by @TempleUniv School of Pharmacy - @TU_SP - with its Pharmaceutical Innovation Award as the university celebrates its 125th anniversary.
Join us for a forward-looking, evidence-focused conversation about regenerative medicine, biotechnology, and the future of healthcare.
Watch now - youtube.com/watch?v=Y09JHb…
#Biotech #Biotechnology #AIinHealthcare #DrugDevelopment #HealthcareInnovation #ProgressPotentialAndPossibilities @KafkaMediaGroup
From rapidly evolving technologies and AI to shifting regulations, payer dynamics, and the economics of drug development, building a biotech company today requires far more than promising ressPotent1 episode, I'm joined by Dr. Stella Vnook - pharmaceutical executive, biotech entrepreneur, and founder of Oral BioLife and AVIVA Ventures.
With more than 25 years of experience spanning Merck, Catalent, and multiple biotechnology ventures, Stella brings a unique perspective on what it takes to turn scientific discoveries into real-world medical innovations.
We explore:
🦷 Regenerative dentistry: @oralbiolife and their Ambrilux Dental Gel is being developed to stimulate bone regeneration in periodontal disease. How is the technology intended to work, and what evidence will be needed to demonstrate its effectiveness in humans?
🧪 The next generation of biotech: Why do promising scientific discoveries so often struggle to become successful treatments - and how can we improve the journey from laboratory to patient?
🤖 AI and drug development: Where can AI genuinely accelerate pharmaceutical innovation, and where do the hardest scientific and clinical challenges remain?
💡 The business of healthcare innovation: How do funding, commercialization, reimbursement, and patient access determine whether a medical breakthrough ultimately makes a difference?
Dr. Vnook is also being recognized by @TempleUniv School of Pharmacy - @TU_SP - with its Pharmaceutical Innovation Award as the university celebrates its 125th anniversary.
Join us for a forward-looking, evidence-focused conversation about regenerative medicine, biotechnology, and the future of healthcare.
Watch now - youtube.com/watch?v=Y09JHb…
#Biotech #Biotechnology #AIinHealthcare #DrugDevelopment #HealthcareInnovation #ProgressPotentialAndPossibilities @KafkaMediaGroup
1
0
3
223
What happens when immunotherapy stops working?
Head and neck squamous cell carcinoma remains a difficult cancer to treat - particularly when tumors recur or progress after prior therapies.
But antibody engineering is opening some fascinating new possibilities.
On this e, I’m joined by Dr. Tahamtan Ahmadi, M.D., Ph.D. - Chief Medical Officer and EVP, Head of Experimental Medicines at @Genmab , to explore the next generation of antibody therapeutics.
At the center of our conversation is petosemtamab, a bispecific antibody designed to simultaneously target EGFR and LGR5.
Why those two targets?
Because the goal isn't simply to block a cancer signal. The molecule is being engineered to potentially do several things at once - including disrupting EGFR signaling, promoting EGFR internalization and degradation through LGR5, and engaging immune-mediated tumor-cell killing.
And that's what makes this story particularly interesting:
Can antibody engineering move us beyond the traditional “one antibody, one target” paradigm?
We also discuss:
• Why head and neck cancer has historically been such a difficult therapeutic problem;
• What happens biologically when tumors progress after immunotherapy;
• Why EGFR has been such an important target - and why targeting EGFR alone hasn't solved the problem;
• What LGR5 may add to the equation;
• The Phase 2 clinical data behind petosemtamab
• The transition from later-line disease into first-line treatment;
• And what the ongoing Phase 3 trials will need to demonstrate before this approach can truly change clinical practice;
It's a fascinating look at where cancer biology, antibody engineering and clinical medicine intersect.
#HeadAndNeckCancer #CancerResearch #Oncology #Immunotherapy #AntibodyEngineering #BispecificAntibodies #Petosemtamab #Genmab @RealChemistry_
Head and neck squamous cell carcinoma remains a difficult cancer to treat - particularly when tumors recur or progress after prior therapies.
But antibody engineering is opening some fascinating new possibilities.
On this e, I’m joined by Dr. Tahamtan Ahmadi, M.D., Ph.D. - Chief Medical Officer and EVP, Head of Experimental Medicines at @Genmab , to explore the next generation of antibody therapeutics.
At the center of our conversation is petosemtamab, a bispecific antibody designed to simultaneously target EGFR and LGR5.
Why those two targets?
Because the goal isn't simply to block a cancer signal. The molecule is being engineered to potentially do several things at once - including disrupting EGFR signaling, promoting EGFR internalization and degradation through LGR5, and engaging immune-mediated tumor-cell killing.
And that's what makes this story particularly interesting:
Can antibody engineering move us beyond the traditional “one antibody, one target” paradigm?
We also discuss:
• Why head and neck cancer has historically been such a difficult therapeutic problem;
• What happens biologically when tumors progress after immunotherapy;
• Why EGFR has been such an important target - and why targeting EGFR alone hasn't solved the problem;
• What LGR5 may add to the equation;
• The Phase 2 clinical data behind petosemtamab
• The transition from later-line disease into first-line treatment;
• And what the ongoing Phase 3 trials will need to demonstrate before this approach can truly change clinical practice;
It's a fascinating look at where cancer biology, antibody engineering and clinical medicine intersect.
#HeadAndNeckCancer #CancerResearch #Oncology #Immunotherapy #AntibodyEngineering #BispecificAntibodies #Petosemtamab #Genmab @RealChemistry_
0
1
3
181
What happens when immunotherapy stops working?
Head and neck squamous cell carcinoma remains a difficult cancer to treat - particularly when tumors recur or progress after prior therapies.
But antibody engineering is opening some fascinating new possibilities.
On this e, I’m joined by Dr. Tahamtan Ahmadi, M.D., Ph.D. - Chief Medical Officer and EVP, Head of Experimental Medicines at @Genmab, to explore the next generation of antibody therapeutics.
At the center of our conversation is petosemtamab, a bispecific antibody designed to simultaneously target EGFR and LGR5.
Why those two targets?
Because the goal isn't simply to block a cancer signal. The molecule is being engineered to potentially do several things at once - including disrupting EGFR signaling, promoting EGFR internalization and degradation through LGR5, and engaging immune-mediated tumor-cell killing.
And that's what makes this story particularly interesting:
Can antibody engineering move us beyond the traditional “one antibody, one target” paradigm?
We also discuss:
• Why head and neck cancer has historically been such a difficult therapeutic problem;
• What happens biologically when tumors progress after immunotherapy;
• Why EGFR has been such an important target - and why targeting EGFR alone hasn't solved the problem;
• What LGR5 may add to the equation;
• The Phase 2 clinical data behind petosemtamab
• The transition from later-line disease into first-line treatment;
• And what the ongoing Phase 3 trials will need to demonstrate before this approach can truly change clinical practice;
It's a fascinating look at where cancer biology, antibody engineering and clinical medicine intersect.
Watch now - youtube.com/watch?v=lyrbUk…
#HeadAndNeckCancer #CancerResearch #Oncology #Immunotherapy #AntibodyEngineering #BispecificAntibodies #Petosemtamab #Genmab @RealChemistry_
Head and neck squamous cell carcinoma remains a difficult cancer to treat - particularly when tumors recur or progress after prior therapies.
But antibody engineering is opening some fascinating new possibilities.
On this e, I’m joined by Dr. Tahamtan Ahmadi, M.D., Ph.D. - Chief Medical Officer and EVP, Head of Experimental Medicines at @Genmab, to explore the next generation of antibody therapeutics.
At the center of our conversation is petosemtamab, a bispecific antibody designed to simultaneously target EGFR and LGR5.
Why those two targets?
Because the goal isn't simply to block a cancer signal. The molecule is being engineered to potentially do several things at once - including disrupting EGFR signaling, promoting EGFR internalization and degradation through LGR5, and engaging immune-mediated tumor-cell killing.
And that's what makes this story particularly interesting:
Can antibody engineering move us beyond the traditional “one antibody, one target” paradigm?
We also discuss:
• Why head and neck cancer has historically been such a difficult therapeutic problem;
• What happens biologically when tumors progress after immunotherapy;
• Why EGFR has been such an important target - and why targeting EGFR alone hasn't solved the problem;
• What LGR5 may add to the equation;
• The Phase 2 clinical data behind petosemtamab
• The transition from later-line disease into first-line treatment;
• And what the ongoing Phase 3 trials will need to demonstrate before this approach can truly change clinical practice;
It's a fascinating look at where cancer biology, antibody engineering and clinical medicine intersect.
Watch now - youtube.com/watch?v=lyrbUk…
#HeadAndNeckCancer #CancerResearch #Oncology #Immunotherapy #AntibodyEngineering #BispecificAntibodies #Petosemtamab #Genmab @RealChemistry_
0
0
2
346
🩺 Can the flu really hospitalize a healthy 19-year-old athlete?
Zach Lang was a physically fit college student and former collegiate wrestler who thought he had a common cold. But in January 2025, he was diagnosed with Influenza A and dangerously elevated creatine kinase re muscle breakdown that put his kidneys at risk.
After three days in the hospital and about a month of recovery, Zach's perspective on influenza changed dramatically.
Now a public health advocate with @famfightflu, Zach joins me on @ProgressPotent1 to share his personal experience, what he learned about the potential complications of influenza, and why he believes young, healthy people should take flu prevention seriously.
We discuss:
🦠 How a seemingly ordinary illness became a medical emergency;
🧬 Influenza A, muscle breakdown and the risk to kidney function;
🏥 Recognizing when symptoms require medical attention;
💉 Flu vaccination and what it can - and cannot - do;
🎓 Why college students and athletes shouldn't underestimate influenza;
An important conversation about influenza, prevention and the fact that being young and healthy doesn't make us invulnerable.
#Influenza #Flu #FluShot #Vaccines #PublicHealth #FluPrevention #CollegeAthletes #FamiliesFightingFlu #ProgressPotentialAndPossibilities @RealChemistry_ @CSL @CSLBehring @IndianaUniv @IUBloomington
Zach Lang was a physically fit college student and former collegiate wrestler who thought he had a common cold. But in January 2025, he was diagnosed with Influenza A and dangerously elevated creatine kinase re muscle breakdown that put his kidneys at risk.
After three days in the hospital and about a month of recovery, Zach's perspective on influenza changed dramatically.
Now a public health advocate with @famfightflu, Zach joins me on @ProgressPotent1 to share his personal experience, what he learned about the potential complications of influenza, and why he believes young, healthy people should take flu prevention seriously.
We discuss:
🦠 How a seemingly ordinary illness became a medical emergency;
🧬 Influenza A, muscle breakdown and the risk to kidney function;
🏥 Recognizing when symptoms require medical attention;
💉 Flu vaccination and what it can - and cannot - do;
🎓 Why college students and athletes shouldn't underestimate influenza;
An important conversation about influenza, prevention and the fact that being young and healthy doesn't make us invulnerable.
#Influenza #Flu #FluShot #Vaccines #PublicHealth #FluPrevention #CollegeAthletes #FamiliesFightingFlu #ProgressPotentialAndPossibilities @RealChemistry_ @CSL @CSLBehring @IndianaUniv @IUBloomington
0
1
3
209
🩺 Can the flu really hospitalize a healthy 19-year-old athlete?
Zach Lang was a physically fit college student and former collegiate wrestler who thought he had a common cold. But in January 2025, he was diagnosed with Influenza A and dangerously elevated creatine kinase re muscle breakdown that put his kidneys at risk.
After three days in the hospital and about a month of recovery, Zach's perspective on influenza changed dramatically.
Now a public health advocate with @famfightflu, Zach joins me on @ProgressPotent1 to share his personal experience, what he learned about the potential complications of influenza, and why he believes young, healthy people should take flu prevention seriously.
We discuss:
🦠 How a seemingly ordinary illness became a medical emergency;
🧬 Influenza A, muscle breakdown and the risk to kidney function;
🏥 Recognizing when symptoms require medical attention;
💉 Flu vaccination and what it can - and cannot - do;
🎓 Why college students and athletes shouldn't underestimate influenza;
An important conversation about influenza, prevention and the fact that being young and healthy doesn't make us invulnerable.
Watch now - youtube.com/watch?v=CUA-EU…
#Influenza #Flu #FluShot #Vaccines #PublicHealth #FluPrevention #CollegeAthletes #FamiliesFightingFlu #ProgressPotentialAndPossibilities @RealChemistry_ @CSL @CSLBehring @IndianaUniv @IUBloomington
Zach Lang was a physically fit college student and former collegiate wrestler who thought he had a common cold. But in January 2025, he was diagnosed with Influenza A and dangerously elevated creatine kinase re muscle breakdown that put his kidneys at risk.
After three days in the hospital and about a month of recovery, Zach's perspective on influenza changed dramatically.
Now a public health advocate with @famfightflu, Zach joins me on @ProgressPotent1 to share his personal experience, what he learned about the potential complications of influenza, and why he believes young, healthy people should take flu prevention seriously.
We discuss:
🦠 How a seemingly ordinary illness became a medical emergency;
🧬 Influenza A, muscle breakdown and the risk to kidney function;
🏥 Recognizing when symptoms require medical attention;
💉 Flu vaccination and what it can - and cannot - do;
🎓 Why college students and athletes shouldn't underestimate influenza;
An important conversation about influenza, prevention and the fact that being young and healthy doesn't make us invulnerable.
Watch now - youtube.com/watch?v=CUA-EU…
#Influenza #Flu #FluShot #Vaccines #PublicHealth #FluPrevention #CollegeAthletes #FamiliesFightingFlu #ProgressPotentialAndPossibilities @RealChemistry_ @CSL @CSLBehring @IndianaUniv @IUBloomington
0
0
2
299
Progress, Potential, And Possibilities retweeted
What if power could be deployed without building traditional grid infrastructure first?
Beam Global CEO Desmond Wheatley joins @irat1onal on @ProgressPotent1 podcast to discuss off-grid EV charging, energy storage, and disaster response.
🎧 Watch Now: youtube.com/watch?v=oJkVZh…
@Nasdaq: $BEEM
Beam Global CEO Desmond Wheatley joins @irat1onal on @ProgressPotent1 podcast to discuss off-grid EV charging, energy storage, and disaster response.
🎧 Watch Now: youtube.com/watch?v=oJkVZh…
@Nasdaq: $BEEM
0
4
12
966
RETHINKING HUMAN SERVICES: CAN WE BUILD A SYSTEM THAT BETTER SERVES PEOPLE?
Homelessness. Addiction. Mental health. Housing insecurity. Aging. Veterans’ needs. Reentry after incarceration.
These challenges are often treated as separate problems, but for the people experiencing y interconnected. Addressing them requires more than individual programs - it requires coordination, compassion, innovation, and a commitment to seeing the whole person.
On this @ProgressPotent1 episode, I’m joined by Ericka Fusilier, Executive Vice President of External Affairs at @voa_national (Volunteers of America), to explore the evolving landscape of human services and what it will take to meet society’s growing needs.
We discuss the realities facing vulnerable populations, the role of nonprofits in filling critical gaps, and how emerging technologies - from AI to robotics and virtual reality - might open new possibilities for care, connection, and independence.
But technology is only part of the story. How do we measure meaningful outcomes? How can organizations work across complex systems? And how do we innovate while keeping dignity, relationships, and human connection at the center?
The ultimate question isn’t simply how we deliver services - it’s how we build a system that helps people thrive.
#HumanServices #SocialImpact #ArtificialIntelligence #Aging #Homelessness #NonprofitLeadership #VolunteersOfAmerica #ProgressPotentialAndPossibilities @VOATexas
@lauraevansmedia @HUDgov @DeptVetAffairs
Homelessness. Addiction. Mental health. Housing insecurity. Aging. Veterans’ needs. Reentry after incarceration.
These challenges are often treated as separate problems, but for the people experiencing y interconnected. Addressing them requires more than individual programs - it requires coordination, compassion, innovation, and a commitment to seeing the whole person.
On this @ProgressPotent1 episode, I’m joined by Ericka Fusilier, Executive Vice President of External Affairs at @voa_national (Volunteers of America), to explore the evolving landscape of human services and what it will take to meet society’s growing needs.
We discuss the realities facing vulnerable populations, the role of nonprofits in filling critical gaps, and how emerging technologies - from AI to robotics and virtual reality - might open new possibilities for care, connection, and independence.
But technology is only part of the story. How do we measure meaningful outcomes? How can organizations work across complex systems? And how do we innovate while keeping dignity, relationships, and human connection at the center?
The ultimate question isn’t simply how we deliver services - it’s how we build a system that helps people thrive.
#HumanServices #SocialImpact #ArtificialIntelligence #Aging #Homelessness #NonprofitLeadership #VolunteersOfAmerica #ProgressPotentialAndPossibilities @VOATexas
@lauraevansmedia @HUDgov @DeptVetAffairs
0
1
4
112
RETHINKING HUMAN SERVICES: CAN WE BUILD A SYSTEM THAT BETTER SERVES PEOPLE?
Homelessness. Addiction. Mental health. Housing insecurity. Aging. Veterans’ needs. Reentry after incarceration.
These challenges are often treated as separate problems, but for the people experiencing y interconnected. Addressing them requires more than individual programs - it requires coordination, compassion, innovation, and a commitment to seeing the whole person.
On this @ProgressPotent1 episode, I’m joined by Ericka Fusilier, Executive Vice President of External Affairs at @voa_national (Volunteers of America), to explore the evolving landscape of human services and what it will take to meet society’s growing needs.
We discuss the realities facing vulnerable populations, the role of nonprofits in filling critical gaps, and how emerging technologies - from AI to robotics and virtual reality - might open new possibilities for care, connection, and independence.
But technology is only part of the story. How do we measure meaningful outcomes? How can organizations work across complex systems? And how do we innovate while keeping dignity, relationships, and human connection at the center?
The ultimate question isn’t simply how we deliver services - it’s how we build a system that helps people thrive.
Watch now - youtube.com/watch?v=O6rHOC…
#HumanServices #SocialImpact #ArtificialIntelligence #Aging #Homelessness #NonprofitLeadership #VolunteersOfAmerica #ProgressPotentialAndPossibilities @VOATexas @lauraevansmedia @HUDgov @DeptVetAffairs
Homelessness. Addiction. Mental health. Housing insecurity. Aging. Veterans’ needs. Reentry after incarceration.
These challenges are often treated as separate problems, but for the people experiencing y interconnected. Addressing them requires more than individual programs - it requires coordination, compassion, innovation, and a commitment to seeing the whole person.
On this @ProgressPotent1 episode, I’m joined by Ericka Fusilier, Executive Vice President of External Affairs at @voa_national (Volunteers of America), to explore the evolving landscape of human services and what it will take to meet society’s growing needs.
We discuss the realities facing vulnerable populations, the role of nonprofits in filling critical gaps, and how emerging technologies - from AI to robotics and virtual reality - might open new possibilities for care, connection, and independence.
But technology is only part of the story. How do we measure meaningful outcomes? How can organizations work across complex systems? And how do we innovate while keeping dignity, relationships, and human connection at the center?
The ultimate question isn’t simply how we deliver services - it’s how we build a system that helps people thrive.
Watch now - youtube.com/watch?v=O6rHOC…
#HumanServices #SocialImpact #ArtificialIntelligence #Aging #Homelessness #NonprofitLeadership #VolunteersOfAmerica #ProgressPotentialAndPossibilities @VOATexas @lauraevansmedia @HUDgov @DeptVetAffairs
0
0
2
161
What if the future of diabetes treatment depends on WHERE a medicine acts - not just which medicine we use?
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people nventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people nventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
0
1
3
171
What if the future of diabetes treatment depends on WHERE a medicine acts - not just which medicine we use?
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people nventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
Watch now - youtube.com/watch?v=jx6Zfx…
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people nventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
Watch now - youtube.com/watch?v=jx6Zfx…
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
0
1
3
340
🧬 Cancer treatment is advancing. Is patient access keeping up?
Chronic lymphocytic leukemia (CLL) is a powerful example of how modern medicine is changing. Targeted therapies and molecular testing have transformed treatment decisions - but scientific progress alone does not will benefit.
What happens when recommended biomarker testing is missed? When insurance restrictions interfere with treatment decisions? When affordability or disparities influence which therapies patients actually receive?
On this episode of @ProgressPotent1 I’m joined by Kirsten Axelsen - @kjacny - Senior Advisor at Charles River Associates - @News_CRA - and Steve Bloom, President and Chair of the @CllSociety .
We discuss a national assessment of CLL care access, the evidence behind reported gaps in testing and treatment, the role of insurers and pharmacy benefit managers, disparities in care, and potential policy solutions.
We also explore a fundamental question for modern medicine: How do we ensure that advances in precision oncology translate into better care for the people who need them?
Because innovation matters - but so does getting the right care to the right patient.
#CLL #CancerCare #PrecisionMedicine #PatientAccess #HealthcarePolicy #Oncology #ProgressPotentialAndPossibilities @BeOneMedicines
@RealChemistry_ @lymphoma @ACSCAN @BloodCancerUtd
Chronic lymphocytic leukemia (CLL) is a powerful example of how modern medicine is changing. Targeted therapies and molecular testing have transformed treatment decisions - but scientific progress alone does not will benefit.
What happens when recommended biomarker testing is missed? When insurance restrictions interfere with treatment decisions? When affordability or disparities influence which therapies patients actually receive?
On this episode of @ProgressPotent1 I’m joined by Kirsten Axelsen - @kjacny - Senior Advisor at Charles River Associates - @News_CRA - and Steve Bloom, President and Chair of the @CllSociety .
We discuss a national assessment of CLL care access, the evidence behind reported gaps in testing and treatment, the role of insurers and pharmacy benefit managers, disparities in care, and potential policy solutions.
We also explore a fundamental question for modern medicine: How do we ensure that advances in precision oncology translate into better care for the people who need them?
Because innovation matters - but so does getting the right care to the right patient.
#CLL #CancerCare #PrecisionMedicine #PatientAccess #HealthcarePolicy #Oncology #ProgressPotentialAndPossibilities @BeOneMedicines
@RealChemistry_ @lymphoma @ACSCAN @BloodCancerUtd
0
1
2
153